0000000000299746

AUTHOR

Mi Kwon

showing 7 related works from this author

The Genotype of the Donor for the (GT)n Polymorphism in the Promoter/Enhancer of FOXP3 Is Associated with the Development of Severe Acute GVHD but Do…

2015

The FOXP3 gene encodes for a protein (Foxp3) involved in the development and functional activity of regulatory T cells (CD4+/CD25+/Foxp3+), which exert regulatory and suppressive roles over the immune system. After allogeneic stem cell transplantation, regulatory T cells are known to mitigate graft versus host disease while probably maintaining a graft versus leukemia effect. Short alleles (<=(GT)(15)) for the (GT)(n) polymorphism in the promoter/enhancer of FOXP3 are associated with a higher expression of FOXP3, and hypothetically with an increase of regulatory T cell activity. This polymorphism has been related to the development of auto-or alloimmune conditions including type 1 diabetes …

MaleAnálisis de supervivenciatrasplante de células madre hematopoyéticasmedicine.medical_treatmenthumanos:Analytical Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Statistics as Topic::Survival Analysis [Medical Subject Headings]Graft vs Host Diseaselcsh:MedicinePolimorfismo genético:Named Groups::Persons::Age Groups::Adult::Middle Aged [Medical Subject Headings]Hematopoietic stem cell transplantationStem cellsRegiones promotoras genéticas:Analytical Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Genetic Techniques::Genetic Association Studies [Medical Subject Headings]:Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings]Trasplante homólogoIL-2 receptorLymphocytesMasculinoPromoter Regions Geneticlcsh:Sciencemediana edadancianoMultidisciplinaryAdultoFemenino:Analytical Diagnostic and Therapeutic Techniques and Equipment::Surgical Procedures Operative::Transplantation::Cell Transplantation::Stem Cell Transplantation::Hematopoietic Stem Cell Transplantation [Medical Subject Headings]Hematopoietic Stem Cell TransplantationFOXP3Forkhead Transcription Factorsadultoanálisis de supervivenciaMiddle AgedTissue DonorsHumanosestudios de asociación genéticaadulto jovenmedicine.anatomical_structuresurgical procedures operativeCèl·lules T:Chemicals and Drugs::Amino Acids Peptides and Proteins::Proteins::Transcription Factors::Winged-Helix Transcription Factors::Forkhead Transcription Factors [Medical Subject Headings]Female:Phenomena and Processes::Genetic Phenomena::Genotype [Medical Subject Headings]Factores de transcripción en cabeza de tenedorCèl·lules mareTrasplante de células madre hematopoyéticasResearch ArticleAdult:Named Groups::Persons::Age Groups::Adult::Young Adult [Medical Subject Headings]GenotypeGraft-vs-Leukemia EffectRegulatory T cellAncianoT cells:Check Tags::Male [Medical Subject Headings]Graft vs Leukemia Effectfactores de transcripción en cabeza de tenedorHuman leukocyte antigenBiologyEnfermedad injerto contra huéspedLimfòcitsYoung AdultDonantes de tejidos:Named Groups::Persons::Tissue Donors [Medical Subject Headings]:Named Groups::Persons::Age Groups::Adult [Medical Subject Headings]medicineHumansTransplantation Homologous:Named Groups::Persons::Age Groups::Adult::Aged [Medical Subject Headings]Genetic Association StudiesAgedMediana edadTransplantationPolymorphism GeneticEstudios de asociación genéticaEfecto injerto contra leucemialcsh:Rdonantes de tejidostrasplante:Phenomena and Processes::Genetic Phenomena::Genetic Variation::Polymorphism Genetic [Medical Subject Headings]medicine.diseaseSurvival Analysis:Diseases::Immune System Diseases::Graft vs Host Disease [Medical Subject Headings]Transplantation:Analytical Diagnostic and Therapeutic Techniques and Equipment::Surgical Procedures Operative::Transplantation::Transplantation Homologous [Medical Subject Headings]efecto injerto contra leucemiaGraft-versus-host disease:Check Tags::Female [Medical Subject Headings]Immunology:Phenomena and Processes::Immune System Phenomena::Immune System Processes::Transplantation Immunology::Graft vs Host Reaction::Graft vs Tumor Effect::Graft vs Leukemia Effect [Medical Subject Headings]enfermedad injerto contra huésped:Phenomena and Processes::Genetic Phenomena::Genetic Structures::Genome::Genome Components::Genes::Gene Components::Regulatory Elements Transcriptional::Promoter Regions Genetic [Medical Subject Headings]lcsh:QgenotipoGenotipoPLoS ONE
researchProduct

Real-World Evidence of Tisagenlecleucel for the Treatment of Relapsed or Refractory Large B-Cell Lymphoma

2020

Introduction Tisagenlecleucel (tisa-cel) is a second generation, CD19-targeted Chimeric Antigen Receptor (CAR) T-cell therapy for relapsed or refractory (R/R) large B-cell lymphoma (LBCL). The pivotal phase 2 trial JULIET included 93 patients and reported an overall response rate (ORR) of 52% and a complete response rate of 40% among treated patients. However, very little is known regarding its safety and efficacy in the commercial or real-world setting as well as from an intention-to-treat perspective. In our study, we report clinical outcomes of patients with R/R LBCL treated with commercial tisa-cel in 10 Spanish institutions. Methods Data were collected retrospectively from all consecut…

Refractorybusiness.industryImmunologymedicineCancer researchCell BiologyHematologyB-cell lymphomamedicine.diseasebusinessReal world evidenceBiochemistryBlood
researchProduct

Assessing the impact on intestinal microbiome and clinical outcomes of antibiotherapy optimisation strategies in haematopoietic stem cell transplant …

2020

GETH (Grupo Español de Trasplante Hematopoyético y Terapia Celular).

medicine.medical_specialtymedicine.drug_classmedicine.medical_treatment1700Antibioticslcsh:MedicinemicrobiomeGraft vs Host DiseaseHematopoietic stem cell transplantationantibioticsAntimicrobial StewardshipFecesInternal medicinegraft versus host diseasemicrobiotamedicineHumansMulticenter Studies as Topic1506infectionsLongitudinal StudiesProspective StudiesAntibiotic prophylaxisbusiness.industryIncidence (epidemiology)lcsh:RHematopoietic Stem Cell TransplantationGeneral MedicineAntibiotic Prophylaxismedicine.diseaseTransplant RecipientsGastrointestinal MicrobiomeTransplantationObservational Studies as Topicsurgical procedures operativeGraft-versus-host diseaseResearch DesignCase-Control StudiesCohortObservational studybusinessHaematology (Incl Blood Transfusion)BMJ Open
researchProduct

Single umbilical cord blood with or without CD34+ cells from a third-party donor in adults with leukemia

2017

We retrospectively compared the clinical outcomes of adults with acute leukemia who received single-unit umbilical cord blood (UCB) transplantation (sUCBT) (n = 135) or stem cell transplant using coinfusion of a UCB graft with CD34+ cells from a third-party donor (Haplo-Cord) (n = 72) at different institutions within the Grupo Espanol de Trasplante Hematopoyetico. In multivariable analysis, patients in the Haplo-Cord group showed more rapid neutrophil (hazard ratio [HR], 2.3; 95% confidence interval [CI], 1.5-3.3; P < .001) and platelet recovery (HR, 1.6; 95% CI, 1.2-2.3; P = .015) and lower incidence of chronic graft-versus-host disease (GVHD) (relative risk, 0.5; 95% CI, 0.3-0.8; P = .01)…

Acute leukemiamedicine.medical_specialtyendocrine systemTransplantationbusiness.industryHazard ratioMyeloid leukemiaContext (language use)Hematologymedicine.diseaseUmbilical cordGastroenterologyTransplantation03 medical and health sciencesLeukemia0302 clinical medicinemedicine.anatomical_structureGraft-versus-host disease030220 oncology & carcinogenesisInternal medicineImmunologyMedicinebusiness030215 immunology
researchProduct

Hospital and outpatient models for Hematopoietic Stem Cell Transplantation: A systematic review of comparative studies for health outcomes, experienc…

2021

The number of Hematopoietic Stem Cell Transplantations has risen in the past 20 years. The practice of outpatient Hematopoietic Stem Cell Transplantation programs is increasing in an attempt to improve the quality of patient care and reduce the demand for hospital admission. A systematic review of 29 comparative studies between in-hospital and outpatient treatment of Hematopoietic Stem Cell Transplantation, with no restriction by outpatient regime was conducted. This study aims to analyse the current evidence on the effects of the outpatient model on patient-centred outcomes, comparing both in-hospital and outpatient models for autologous and allogeneic HSCT using the Triple Aim framework: …

Cell Transplantationmedicine.medical_treatmentFeversHematopoietic stem cell transplantationHealth careOutpatientsMedicine and Health SciencesBlood and Lymphatic System ProceduresOutpatient clinicMultidisciplinaryMortality rateQRHematopoietic Stem Cell TransplantationHematopoietic stem cellResearch AssessmentHospitalsSurvival Ratemedicine.anatomical_structureSystematic reviewModels EconomicCosts and Cost AnalysisMedicineResearch Articlemedicine.medical_specialtyPatientsSystematic ReviewsDeath RatesScienceSurgical and Invasive Medical ProceduresHealth outcomesResearch and Analysis MethodsTransplantation AutologousDisease-Free SurvivalQuality of life (healthcare)Signs and SymptomsPopulation MetricsmedicineHumansTransplantation HomologousIntensive care medicineOutpatient ClinicsTransplantationInpatientsPopulation Biologybusiness.industryBiology and Life SciencesLength of StayHealth CareHealth Care FacilitiesQuality of LifeClinical MedicinebusinessStem Cell TransplantationPloS one
researchProduct

Real‐world evidence of tisagenlecleucel for the treatment of relapsed or refractory large B‐cell lymphoma

2021

Abstract Tisagenlecleucel (tisa‐cel) is a second‐generation autologous CD19‐targeted chimeric antigen receptor (CAR) T‐cell therapy approved for relapsed/refractory (R/R) large B‐cell lymphoma (LBCL). The approval was based on the results of phase II JULIET trial, with a best overall response rate (ORR) and complete response (CR) rate in infused patients of 52% and 40%, respectively. We report outcomes with tisa‐cel in the standard‐of‐care (SOC) setting for R/R LBCL. Data from all patients with R/R LBCL who underwent leukapheresis from December 2018 until June 2020 with the intent to receive SOC tisa‐cel were retrospectively collected at 10 Spanish institutions. Toxicities were graded accor…

Male0301 basic medicine:aminoácidos péptidos y proteínas::proteínas::proteínas de membranas::receptores de superficie celular::receptores inmunológicos::receptores de antígenos::receptores de antígenos de linfocitos T [COMPUESTOS QUÍMICOS Y DROGAS]Cancer Researchnon‐Hodgkin's lymphomaBest Overall Responsehematological cancer:Other subheadings::Other subheadings::/drug therapy [Other subheadings]Non- Hodgkin's lymphomaGastroenterology0302 clinical medicineMedicine research:Other subheadings::/therapeutic use [Other subheadings]CàncerB-cell lymphomaRC254-282CancerOriginal ResearchReceptors Chimeric AntigenNeoplasms. Tumors. Oncology. Including cancer and carcinogensnon&#8208Standard of CareMiddle AgedPatologiaHodgkin&aposProgression-Free SurvivalCytokine release syndromeclinical cancer researchOncology:neoplasias::neoplasias por tipo histológico::linfoma::linfoma no Hodgkin::linfoma de células B::linfoma de células B grandes difuso [ENFERMEDADES]030220 oncology & carcinogenesisCytokinesFemaleLymphoma Large B-Cell Diffusenon-Hodgkin's lymphomamedicine.medical_specialtyReceptors Antigen T-CellCèl·lules B - Tumors - Tractament:Otros calificadores::Otros calificadores::/farmacoterapia [Otros calificadores]Investigació mèdicaReal world evidence03 medical and health sciencess lymphoma:Neoplasms::Neoplasms by Histologic Type::Lymphoma::Lymphoma Non-Hodgkin::Lymphoma B-Cell::Lymphoma Large B-Cell Diffuse [DISEASES]Refractoryclinical observationsInternal medicinemedicineHumansRadiology Nuclear Medicine and imagingLeukapheresis:Amino Acids Peptides and Proteins::Proteins::Membrane Proteins::Receptors Cell Surface::Receptors Immunologic::Receptors Antigen::Receptors Antigen T-Cell [CHEMICALS AND DRUGS]AgedRetrospective Studies:Otros calificadores::/uso terapéutico [Otros calificadores]business.industryTeràpia cel·lularClinical Cancer ResearchLeukapheresismedicine.diseaseMalaltia de HodgkinNon-Hodgkin's lymphomaLymphoma030104 developmental biologyHodgkin's diseaseNeoplasm Recurrence LocalbusinessCancer Medicine
researchProduct

Post-transplantation cyclophosphamide after HLA identical compared to haploidentical donor transplant in acute myeloid leukemia: a study on behalf of…

2022

Post-transplantation cyclophosphamide (PTCY) effectively prevents graft-versus-host disease (GVHD) after unmanipulated HLA-haploidentical hematopoietic stem cell transplantation (HSCT) and achieves low rates of GVHD in HLA-identical transplantation. To compare the outcomes of haploidentical versus HLA identical HSCT in patients undergoing HSCT for acute myeloid leukemia (AML) using PTCY. We conducted a retrospective study of 229 patients undergoing first HSCT for AML using PTCY with additional immunosuppression, 99 from matched sibling or unrelated donor (MSD/MUD) performed in 3 hospitals and 130 from haploidentical donors (haplo group) performed in 20 hospitals within the Spanish Group of …

TransplantationTransplantation of organsAcute myeloid leukemiaTransplantation ConditioningLeucèmia mieloideCèl·lulesCell BiologyHematologyTrasplantament d'òrgansLeukemia Myeloid AcuteMyeloid leukemiasurgical procedures operativeGVHD prophylaxisHumansMolecular MedicineImmunology and AllergyPost-transplantation cyclophosphamideUnrelated DonorsCyclophosphamideRetrospective Studies
researchProduct